Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Nabilone for Agitation Blinded Intervention Trial
Authors not listed
Sunnybrook Health Sciences Centre · 2021
Abstract
This study will look at whether nabilone is an effective treatment for agitation in Alzheimer's disease (AD) patients. Agitation is highly prevalent in patients with AD and is one of the most distressing and challenging-to-treat symptoms. Agitation is associated with faster progression to institutionalization, increased caregiver burden, poorer quality of life, and increased risk of death. In addition, current pharmacological options show only modest efficacy and elevated risks of adverse events. Therefore, identifying safer and more effective treatments for agitation in AD is a clinical and research priority.
Nabilone is a synthetic cannabinoid that is Health Canada-approved to treat chemotherapy-induced nausea and vomiting.
The PI's research group completed a 6-week double-blind placebo-controlled randomized cross-over pilot trial in 38 patients with moderate-to-severe AD, providing the first preliminary evidence regarding the safety and efficacy of nabilone in this population. They found that nabilone significantly improved agitation, overall neuropsychiatric symptoms, and caregiver distress. That study was limited by its sample size and questions remain regarding the efficacy of nabilone for nutrition and pain and predictors of response. However, the promising preliminary findings encourage a pivotal, practice-changing phase III trial to inform clinical practice.
Participants in this study will be randomized to receive either nabilone or a placebo for 8 weeks. In addition to looking at the effectiveness of nabilone in treating agitation, the researchers will also look at whether it is beneficial for other relevant outcomes for patients with AD including overall neuropsychiatric symptoms, caregiver distress, cognition, nutritional status, and pain. Participants will also be followed for 8 weeks following completion of the study treatment.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-19 MST
Cite this
APA
Anonymous. (2021). Nabilone for Agitation Blinded Intervention Trial. <em>Sunnybrook Health Sciences Centre</em>. https://clinicaltrials.gov/study/NCT04516057
Vancouver
Anonymous. Nabilone for Agitation Blinded Intervention Trial. Sunnybrook Health Sciences Centre. 2021.
BibTeX
@misc{anon2021Nabilo,
title = {Nabilone for Agitation Blinded Intervention Trial},
author = {Anonymous},
journal = {Sunnybrook Health Sciences Centre},
year = {2021},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Saint John's Cancer Institute 2019
Open access · US-GOV
The PREVENTION Trial: Precision Recommendations for Environmental Variables, Exercise, Nutrition and Training Interventions to Optimize Neurocognition
Eduarda Oliosi, MS 2026
Open access · US-GOV
Exercogs®: Efficacy of a Multidomain Digital Therapeutic Solution for Preventing Cognitive Decline in Adults Aged ≥55 With Modifiable Risk Factors - Randomized Controlled Trial
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau 2025
Open access · US-GOV
A Phase III, Randomized, Double-blinded Study of the Efficacy and Safety of LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome (the LESS-AD Trial).
The University of Hong Kong 2021
Open access · US-GOV
Qigong to Improve Frailty Among Older Cancer Survivors: A Randomized Controlled Trial
Vestre Viken Hospital Trust 2024
Open access · US-GOV
INTEgRated Health CARE for Patients With Frailty and Heart Failure (INTERCARE-HF): Evaluation of an Innovation Project
Centre for Addiction and Mental Health 2018
Open access · US-GOV